Table 3

Drug response SNPs
# Drug/Condition Chromosomal location Gene Genotype SNP-ID Drug related outcome
1 Interferon beta therapy for multiple sclerosis (MS) chr13:92884370 GPC5 CT rs7987675 will likely not show increase response to interferon beta therapy in case of relapsed MS
2 Lumiracoxib-related liver toxicity chr6:32305978 C6orf10 GT rs3129900 increase in liver toxicity risk in response to lumiracoxib used to treat acute pain and osteoarthritic symptoms
3 Metformin Response chr11:108239628 ATM-C11orf65 GG rs4585 will respond better to Metformin
4 Ribavirin-induced anemia chr20:3193842 ITPA CA rs1127354 greatly decreased odds of developing anemia when taking PEG-IFN/RBV
5 Statin induced myopathy chr12:21331549 SLCO1B1 TT rs4149056 typical dose of Simvastin will not increase myopathy risk
6 Floxacillin and liver toxicity chr6:31431780 HCP5 TT rs2395029 at typical dose liver toxicity is not expected in response to floxacillin
7 Beta-Blocker - heart failure risk chr10:115805056 ADRB1 CC rs1801253 Bucindolol is unlikely to reduce mortality odds in case of heart failure
8 Response to amitriptyline chr7:87160561 ABCB1 AA rs2032583 typical response to depression when treated with Elavil, Paxil, Effexor, or Celexa
9 Warfarin sensitivity chr10:96702047 CYP2C9 CC rs1799853 typical dose of warfarin does not increase risk of bleeding
chr10:96741053 CYP2C9 AA rs1057910
chr16:31107689 VKORC1 CC rs9923231
promoter
10 Fluorouracil toxicity chr1:97915613 DPYD CC rs3918290 No copies of the DPYD*2A mutation. May still be at risk for 5-FU toxicity due to other genetic or non-genetic factors

Gupta et al.

Gupta et al. BMC Genomics 2012 13:440   doi:10.1186/1471-2164-13-440

Open Data